Markets
MCC

Medley Capital Settles MusclePharm Litigation

Medley Capital ( MCC ) said late Monday that it has successfully reached a settlement agreement with MusclePharm Corporation for claims MusclePharm made against Medley and its portfolio company, Capstone Nutrition.

Under the settlement, MusclePharm must pay Capstone an undisclosed cash amount and other consideration, which it will use in connection with its obligations to Medley, including a Medley-led term loan. MusclePharm will also drop all claims against both Medley and Capstone and dismiss its complaint with prejudice.

Capstone initially filed a complaint against MusclePharm on May 16, 2016 for multiple contractual breaches, including non-payment for product and failure to meet minimum volume requirements.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MCC

Other Topics

ETFs